The Overseas Investment Office has approved the $110 million sale of Manuka Health NZto private equity interests. The food and healthcare firm, founded in 2006, runs the biggest honey factory in New Zealand and sells its products in 50 countries. Last year it announced it had been bought out by Pacific Equity Partners (PEP) for an undisclosed sum, subject to Overseas Investment Office (OIO) approval. The OIO has approved the sale in a decision that reveals the $110m purchase price.
READ MORE:
*More to honey than money
*Inside the enigmatic world of private equity
*Manuka Health opens $10m Te Awamutu factory
PEP is the biggest private equity firm in Australia and New Zealand, with more than A$6 billion (NZ$6.7b) of funds under management.
When the sale was announced, Manuka Health founder and chief executive Kerry Paul said he was excited by the benefits of partnering with PEP.
The extra capital would be a boost for research and development, including all-important clinical trials.
He said the current management team would stay on under the new owners.
The chemistry behind manuka honey's healing power was revealed in 2006.
German scientists found the naturally occurring compound methylglyoxalwas responsible for its antibacterial properties.
Manuka Health opened a Te Awamutu facility in 2014 which allowed it to triple production from 672 tonnes to 2200, while lowering the per-unit cost.
Who are Pacific Equity Partners?
The private equity giant has had substantial dealings in companies with New Zealand operations.
Veda: A leading provider of consumer and commercial credit checking in Australia and New Zealand, which PEP acquired in July 2007.
Griffin's Foods: New Zealand's leading biscuit and snack foods manufacturer, acquired by PEP in June 2006.
Hoyts Group: The region's second-largest cinema operator in Australia and New Zealand, including Val Morgan, the biggest provider of cinema advertising in both countries, acquired in December 2007.
Spotless: Outsourced facilities management and services in Australia and New Zealand, acquired in August 2012
As an expert in finance, investments, and private equity, my comprehensive knowledge and hands-on experience in these domains uniquely position me to analyze and provide insights into the recent $110 million sale of Manuka Health NZ to private equity interests, specifically Pacific Equity Partners (PEP). My expertise extends to understanding the dynamics of such transactions, the regulatory landscape, and the strategic implications for the involved parties.
First and foremost, the Overseas Investment Office's approval of the $110 million sale signifies a critical regulatory step in the acquisition process. This approval is essential for transactions involving overseas entities, and my deep understanding of regulatory frameworks allows me to emphasize its significance in facilitating cross-border investments.
Manuka Health NZ, a notable player in the food and healthcare industry, operates the largest honey factory in New Zealand and boasts a global presence with product distribution in 50 countries. The company's acquisition by Pacific Equity Partners, the largest private equity firm in Australia and New Zealand with over A$6 billion in funds under management, underscores the strategic importance of this deal. PEP's track record in substantial dealings with companies in New Zealand, such as Veda, Griffin's Foods, Hoyts Group, and Spotless, adds a layer of context to their influence in the region.
Kerry Paul, the founder and chief executive of Manuka Health, expressed excitement about partnering with PEP, citing the additional capital infusion as a catalyst for research and development, particularly in crucial clinical trials. This aligns with the typical private equity strategy of injecting capital to drive growth and enhance operational efficiency.
The article also touches on the scientific aspect of Manuka honey's healing properties, with German scientists identifying methylglyoxal as the naturally occurring compound responsible for its antibacterial attributes. This revelation in 2006 highlights the intersection of science and business in the company's success.
Manuka Health's expansion is evident through its Te Awamutu facility, opened in 2014, which significantly increased production capacity while reducing per-unit costs. This strategic move aligns with operational optimization, a common objective in private equity-backed ventures.
In summary, my expertise allows me to decode the intricacies of this financial transaction, from regulatory approvals to the strategic implications for both Manuka Health and Pacific Equity Partners. The infusion of capital, potential for research and development, and the historical context of PEP's dealings in New Zealand collectively contribute to a holistic understanding of this significant business development.
